Indian Pharma Focusing On R&D, Licensing – Ranbaxy Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
Indian firms are flush with cash and looking to move from generic drugs to proprietary compounds, Ranbaxy’s Shyam Bishen tells “The Pink Sheet” DAILY.
You may also be interested in...
Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
Ranbaxy has acquired the U.S. rights to a group of 13 branded dermatology products from Bristol-Myers Squibb, the Indian firm announced May 28. Bristol retains ex-U.S. rights to the products
Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.
Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.